Literature DB >> 21684121

Topiramate-induced weight loss: a review.

Alberto Verrotti1, Alessandra Scaparrotta, Sergio Agostinelli, Sabrina Di Pillo, Francesco Chiarelli, Salvatore Grosso.   

Abstract

BACKGROUND: Weight loss can occur during topiramate (TPM) treatment and it should be evaluated by clinicians, especially in children, whose growth could be compromised. In international literature, the reported body weight loss incidences linked to TPM therapy vary widely and, in some cases, are very conflicting. AIMS: The aims of this review are to quantify TPM-induced weight loss, analyze the pathogenetic mechanisms and evaluate its clinical implications in patients with epilepsy.
RESULTS: The amount of weight loss appears to be related to some factors such as the duration of the treatment and a high baseline body mass index (BMI), while the role of daily dosage and gender of patients is controversial. The mechanism through which TPM may induce weight loss is still unclear.
INTERPRETATION: TPM is able to induce weight loss, especially in high baseline BMI patients, not strictly depending on daily dosage and perhaps not influenced by gender. This makes TPM a good choice, especially in obese patients suffering from seizures. However, TPM can make nutritionally vulnerable children or adult patients, with epilepsy associated with other neuropsychiatric diseases, who cannot voluntarily increase their caloric intake.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21684121     DOI: 10.1016/j.eplepsyres.2011.05.014

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  23 in total

Review 1.  New pharmacological approaches for obesity management.

Authors:  Christian F Rueda-Clausen; Raj S Padwal; Arya M Sharma
Journal:  Nat Rev Endocrinol       Date:  2013-06-11       Impact factor: 43.330

2.  Topiramate for weight reduction in adolescents with severe obesity.

Authors:  Claudia K Fox; Kara L Marlatt; Kyle D Rudser; Aaron S Kelly
Journal:  Clin Pediatr (Phila)       Date:  2014-07-14       Impact factor: 1.168

Review 3.  Treatment of clozapine-associated weight gain: a systematic review.

Authors:  Z Whitney; R M Procyshyn; D H Fredrikson; A M Barr
Journal:  Eur J Clin Pharmacol       Date:  2015-01-28       Impact factor: 2.953

4.  Effects of topiramate use on body composition and resting metabolic rate in migraine patients.

Authors:  Mehmet Yaman; Kagan Ucok; Hayri Demirbas; Abdurrahman Genc; Serdar Oruc; Hatice Karabacak; Gokhan Koyuncu
Journal:  Neurol Sci       Date:  2012-03-06       Impact factor: 3.307

5.  Regulation of high glucose-induced apoptosis of brain pericytes by mitochondrial CA VA: A specific target for prevention of diabetic cerebrovascular pathology.

Authors:  Tulin O Price; Nader Sheibani; Gul N Shah
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-01-26       Impact factor: 5.187

6.  Topiramate effects lipolysis in 3T3-L1 adipocytes.

Authors:  Gabriela Poltronieri Campagnaro Martins; Camila Oliveira Souza; Scherolin Marques; Thais Fernandes Luciano; Bruno Luiz DA Silva Pieri; José César Rosa; Adelino Sanchez Ramos DA Silva; José Rodrigo Pauli; Dennys Esper Cintra; Eduardo Rochete Ropelle; Bruno Rodrigues; Fabio Santos DE Lira; Claudio Teodoro DE Souza
Journal:  Biomed Rep       Date:  2015-08-28

Review 7.  Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.

Authors:  Kishore M Gadde; Y Pritham Raj
Journal:  Curr Diab Rep       Date:  2017-05       Impact factor: 4.810

Review 8.  The long-term safety of antiepileptic drugs.

Authors:  Athanasios Gaitatzis; Josemir W Sander
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 9.  Targeting adipose tissue in the treatment of obesity-associated diabetes.

Authors:  Christine M Kusminski; Perry E Bickel; Philipp E Scherer
Journal:  Nat Rev Drug Discov       Date:  2016-06-03       Impact factor: 84.694

10.  Topiramate's reduction of body mass index in heavy drinkers: lack of moderation by a GRIK1 polymorphism.

Authors:  Henry R Kranzler; Richard Feinn; Joel Gelernter; Timothy Pond; Jonathan Covault
Journal:  Exp Clin Psychopharmacol       Date:  2014-06-30       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.